Fluorinated aminotriazole derivatives

1. A compound of the formula (I),

wherein

A represents a heteroaryl-group, wherein the two attachment-points of said heteroaryl-group are in a 1,3-arrangement;

R 1 represents phenyl which is unsubstituted, mono- or di-substituted, wherein the substituents independently is halogen, methyl, methoxy, trifluoromethyl, trifluoromethoxy or dimethylamino; and

R 2 represents hydrogen, methyl, ethyl or cyclopropyl;

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 ,

wherein

A represents a group selected from furanyl, oxazolyl or thiazolyl, wherein the two attachment-points of said group are in a 1,3-arrangement;

R 1 represents phenyl which is unsubstituted, mono- or di-substituted, wherein the substituents independently is fluoro, chloro, methyl, methoxy, trifluoromethyl, trifluoromethoxy or dimethylamino; and

R 2 represents hydrogen, methyl or ethyl;

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 2 , wherein A represents furan-2,5-diyl, oxazol-2,4-diyl or thiazol-2,4-diyl; or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 2 , wherein A represents furan-2,5-diyl; or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 2 , wherein A represents oxazol-2,4-diyl; or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 2 , wherein A represents thiazol-2,4-diyl; or a pharmaceutically acceptable salt thereof.

7. The compound according to claim 2 , wherein R 1 represents unsubstituted phenyl; or a pharmaceutically acceptable salt thereof.

8. The compound according to claim 2 , wherein R 1 represents phenyl, which is mono-substituted with fluoro, chloro, methyl or trifluoromethyl; or a pharmaceutically acceptable salt thereof.

9. The compound according to claim 8 , wherein R 2 represents hydrogen; or a pharmaceutically acceptable salt thereof.

10. The compound according to claim 8 , wherein R 2 represents methyl or ethyl; or a pharmaceutically acceptable salt thereof.

11. The compound according to claim 1 , selected from:

2-Methyl-5-m-tolyl-oxazole-4-carboxylic acid {2-[5-(1,1-difluoro-ethyl)-furan-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

5-Phenyl-oxazole-4-carboxylic acid {2-[4-(1,1-difluoro-ethyl)-thiazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

2-Methyl-5-m-tolyl-oxazole-4-carboxylic acid {2-[4-(1,1-difluoro-ethyl)-thiazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

2-Methyl-5-phenyl-oxazole-4-carboxylic acid {2-[5-(1,1-difluoro-ethyl)-furan-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

5-(3,5-Difluoro-phenyl)-2-methyl-oxazole-4-carboxylic acid {2-[4-(1,1-difluoro-ethyl)-thiazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

2-Methyl-5-(3-trifluoromethyl-phenyl)-oxazole-4-carboxylic acid {2-[4-(1,1-difluoro-ethyl)-thiazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

5-(3-Chloro-phenyl)-oxazole-4-carboxylic acid {2-[5-(1,1-difluoro-ethyl)-furan-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

5-(3-Methoxy-phenyl)-oxazole-4-carboxylic acid {2-[4-(1,1-difluoro-ethyl)-thiazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

2-Cyclopropyl-5-phenyl-oxazole-4-carboxylic acid {2-[4-(1,1-difluoro-ethyl)-thiazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

2-Methyl-5-phenyl-oxazole-4-carboxylic acid {2-[4-(1,1-difluoro-ethyl)-thiazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

5-(3-Fluoro-phenyl)-oxazole-4-carboxylic acid {2-[5-(1,1-difluoro-ethyl)-furan-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

5-(3-Chloro-phenyl)-oxazole-4-carboxylic acid {2-[4-(1,1-difluoro-ethyl)-thiazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

5-(3-Fluoro-5-methyl-phenyl)-2-methyl-oxazole-4-carboxylic acid {2-[4-(1,1-difluoro-ethyl)-thiazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

2-Methyl-5-(3-trifluoromethoxy-phenyl)-oxazole-4-carboxylic acid {2-[4-(1,1-difluoro-ethyl)-thiazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

5-(3-Chloro-phenyl)-2-methyl-oxazole-4-carboxylic acid {2-[5-(1,1-difluoro-ethyl)-furan-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

5-(4-Fluoro-phenyl)-oxazole-4-carboxylic acid {2-[5-(1,1-difluoro-ethyl)-furan-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

5-m-Tolyl-oxazole-4-carboxylic acid {2-[4(1,1-difluoro-ethyl)-thiazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

5-(3,5-Difluoro-phenyl)-2-methyl-oxazole-4-carboxylic acid {2-[5-(1,1-difluoro-ethyl)-furan-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

5-(3-Dimethylamino-phenyl)-oxazole-4-carboxylic acid {2-[5-(1,1-difluoro-ethyl)-furan-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

5-(3-Fluoro-phenyl)-oxazole-4-carboxylic acid {2-[4-(1,1-difluoro-ethyl)-thiazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

5-(3-Methoxy-phenyl)-oxazole-4-carboxylic acid {2-[5-(1,1-difluoro-ethyl)-furan-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

5-(3-Dimethylamino-phenyl)-oxazole-4-carboxylic acid {2-[4-(1,1-difluoro-ethyl)-thiazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}amide;

5-m-Tolyl-oxazole-4-carboxylic acid {2-[5-(1,1-difluoro-ethyl)-furan-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

2-Methyl-5-(3-trifluoromethyl-phenyl)-oxazole-4-carboxylic acid {2-[5(1,1-difluoro-ethyl)-furan-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}amide;

5-(4-Fluoro-phenyl)-oxazole-4-carboxylic acid {2-[4-(1,1-difluoro-ethyl)-thiazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

5-(3-Fluoro-5-methyl-phenyl)-2-methyl-oxazole-4-carboxylic acid {2-[5-(1,1-difluoro-ethyl)-furan-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}amide;

2-Methyl-5-(3-trifluoromethoxy-phenyl)-oxazole-4-carboxylic acid {2-[5-(1,1-difluoro-ethyl)-furan-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

5-Phenyl-oxazole-4-carboxylic acid {2-[5-(1,1-difluoro-ethyl)-furan-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

5-(3-Chloro-phenyl)-2-methyl-oxazole-4-carboxylic acid {2-[4-(1,1-difluoro-ethyl)-thiazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

2-Ethyl-5-phenyl-oxazole-4-carboxylic acid {2-[4-(1,1-difluoro-ethyl)-thiazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}amide; or

2-Methyl-5-m-tolyl-oxazole-4-carboxylic acid {2-[4(1,1-difluoro-ethyl)-oxazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

or a pharmaceutically acceptable salt thereof.

12. The compound according to claim 1 , selected from:

N-(2-((2-(1,1-Difluoroethyl)oxazol-4-yl)methyl)-2H-1,2,3-triazol-4-yl)-2-methyl-5-(m-tolyl)oxazole-4-carboxamide;

2-Methyl-5-phenyl-oxazole-4-carboxylic acid {2-[4-(1,1-difluoro-ethyl)-oxazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

5-(3-Dimethylamino-phenyl)-oxazole-4-carboxylic acid {2-[4-(1,1-difluoro-ethyl)-oxazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide;

5-(3-Dimethylamino-4-fluoro-phenyl)-oxazole-4-carboxylic acid {2-[4-(1,1-difluoro-ethyl)-oxazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}amide; or

5-(3-Dimethylamino-4-fluoro-phenyl)-2-methyl-oxazole-4-carboxylic acid {2-[4(1,1-difluoro-ethyl)-oxazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}amide;

or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

14. A method of treating a disease comprising administering to a subject in need thereof, a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein the disease is selected from inflammatory diseases, obstructive airway diseases, allergic conditions, HIV-mediated retroviral infections, cardiovascular disorders, neuroinflammation, neurological disorders, pain, prion-mediated diseases or amyloid-mediated disorders; or for the modulation of immune responses.

15. A method of treating a disease comprising administering to a subject in need thereof, a composition according to claim 13 , wherein the disease is selected from inflammatory diseases, obstructive airway diseases, allergic conditions, HIV-mediated retroviral infections, cardiovascular disorders, neuroinflammation, neurological disorders, pain, prion-mediated diseases or amyloid-mediated disorders; or for the modulation of immune responses.

16. The compound according to claim 5 , wherein R 1 represents phenyl, which is mono-substituted with fluoro, chloro, methyl or trifluoromethyl; or a pharmaceutically acceptable salt thereof.

17. The compound according to claim 6 , wherein R 1 represents phenyl, which is mono-substituted with fluoro, chloro, methyl or trifluoromethyl; or a pharmaceutically acceptable salt thereof.

18. The compound according to claim 1 , wherein the compound is:

2-Methyl-5-phenyl-oxazole-4-carboxylic acid {2-[5-(1,1-difluoro-ethyl)-furan-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide; or a pharmaceutically acceptable salt thereof.

19. The compound according to claim 1 , wherein the compound is:

2-Methyl-5-(3-trifluoromethyl-phenyl)-oxazole-4-carboxylic acid {2-[5-(1,1-difluoro-ethyl)-furan-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide; or a pharmaceutically acceptable salt thereof.

20. The compound according to claim 1 , wherein the compound is:

2-Methyl-5-m-tolyl-oxazole-4-carboxylic acid {2-[4-(1,1-difluoro-ethyl)-oxazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide; or a pharmaceutically acceptable salt thereof.

21. The compound according to claim 1 , wherein the compound is:

2-Methyl-5-phenyl-oxazole-4-carboxylic acid {2-[4-(1,1 -difluoro-ethyl)-oxazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide; or a pharmaceutically acceptable salt thereof.

22. The compound according to claim 1 , wherein the compound is:

5-(3-Chloro-phenyl)-2-methyl-oxazole-4-carboxylic acid {2-[4-(1,1-difluoro-ethyl)-thiazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide; or a pharmaceutically acceptable salt thereof.